# US 8,788,026 B2 · Methods and devices for determination of heart arrhythmia type > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 8,788,026 B2 - Document ID: US8788026B2 - Status: Granted - Kind: B2 - Application number: 13/430,750 - Filed: 2012-03-27 - Published: 2012-10-18 - Granted: 2014-07-22 - Earliest claimed: 2011-04-13 - Assignees: BIOTRONIK SE & Co. KG - Applicants: Jie Lian; Volker Lang - Inventors: Jie Lian; Volker Lang - Web page: https://patentgrep.com/patent/US8788026B2 ## CPC - A61B 5/363: Detecting tachycardia or bradycardia - A61B 5/4839: {combined with drug delivery} - A61M 5/1428: {with manual pumping action} - A61M 5/1723: {using feedback of body parameters, e.g. blood sugar or pressure} - A61N 1/3621: {for treating or preventing abnormally high heart rate} - A61N 1/3956: {Implantable devices for applying electric shocks to the heart, e.g. for cardioversion} - A61B: DIAGNOSIS; SURGERY; IDENTIFICATION (usefulness limited to only animals A61D) - A61M: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY (introducing media into or onto the bodies of animals A61D7/00; means for inserting tampons A61F13/26; devices for administering food or medicines orally A61J; containers for collecting, storing or administering blood or medical fluids A61J1/05); DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY (surgery A61B; chemical aspects of surgical articles A61L); DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR {(Electrotherapy, e.g. producing anaesthesia by the use of alternating or intermittent currents A61N1/36021)} - A61N: ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY (measurement of bioelectric currents A61B; surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body A61B18/00; anaesthetic apparatus in general A61M; incandescent lamps H01K; infrared radiators for heating H05B) ## Abstract The type of arrhythmia in a patient's heart can be determined by monitoring the atrial and ventricular rate of the heart; detecting a pathological initial ventricular and/or atrial rate during a first time period; if a pathological initial rate is detected, then administering at least one antiarrhythmic cardioactive drug over a short second time period; detecting the heart's response to the administered drug(s), as by comparing the responsive ventricular and atrial rates with the initial ventricular and atrial rates, respectively, within a third time period; and determining the type of atrial or ventricular arrhythmia from the presence or absence of differences, and the type of differences, between the responsive atrial and ventricular rates compared with the initial atrial and ventricular rates. The invention further involves a related device which includes an implantable cardiac device (10) and a drug delivery device (20). ## Claims ### Claim 1 A method performed in an implantable system for determining a type of an arrhythmia in a patient's heart, the method including the steps of: a. monitoring initial atrial and ventricular rates of the heart; b. detecting a pathological initial ventricular and/or atrial rate; c. upon detecting a pathological initial ventricular and/or atrial rate during a first time period: (1) administering a nontherapeutic amount of an antiarrhythmic cardioactive drug over a second time period, the nontherapeutic amount being less than a therapeutic amount typically prescribed for the pathological initial ventricular and/or atrial rate; (2) detecting the response of the ventricular and atrial rates to the nontherapeutic amount of the drug; (3) determining differences between: (a) the ventricular and atrial rates in response to the drug, and (b) the initial atrial and ventricular rates; (4) determining a type of atrial or ventricular arrhythmia from the differences. ### Claim 2 (depends on 1) The method of claim 1 wherein the second time period is less than 10 seconds. ### Claim 3 (depends on 1) The method of claim 1 wherein the second time period is 1 to 3 seconds. ### Claim 4 (depends on 1) The method of claim 1 wherein the antiarrhythmic cardioactive drug includes adenosine. ### Claim 5 (depends on 1) The method of claim 1 wherein the antiarrhythmic cardioactive drug is administered intravenously. ### Claim 6 (depends on 1) The method of claim 1 wherein a pathological initial ventricular and atrial rate is detected during the first time period if the atrial rate is greater than or equal to the ventricular rate during the first time period. ### Claim 7 (depends on 6) The method of claim 6 wherein if the ventricular rate has slowed in response to the drug but the atrial rate has not slowed in response to the drug, electrical stimulation is delivered to the heart. ### Claim 8 (depends on 1) The method of claim 1 wherein the differences between: a. the ventricular and atrial rates in response to the drug, and b. the initial atrial and ventricular rates, are determined over a third time period starting after the start of the second time period. ### Claim 9 (depends on 8) The method of claim 8 wherein the third time period starts after the end of the second time period. ### Claim 10 (depends on 8) The method of claim 8 wherein the third time period begins 1-3 seconds after the start of the second time period. ### Claim 11 A method performed in an implantable system for determining a type of an arrhythmia in a patient's heart, the method including the steps of: a. monitoring initial atrial and ventricular rates of the heart; b. detecting a pathological initial ventricular and/or atrial rate wherein the atrial rate is greater than or equal to the ventricular rate; c. upon detecting a pathological initial ventricular and/or atrial rate during a first time period: (1)administering an antiarrhythmic cardioactive drug over a second time period; (2) detecting the response of the ventricular and atrial rates to the drug; (3) determining differences between: (a) the ventricular and atrial rates in response to the drug, and (b) the initial atrial and ventricular rates; (4) determining a type of atrial or ventricular arrhythmia from the differences, wherein if both the ventricular and atrial rates are slowed in response to the drug, an AV nodal dependent SVT is determined. ### Claim 12 A method performed in an implantable system for determining a type of an arrhythmia in a patient's heart, the method including the steps of: a. monitoring initial atrial and ventricular rates of the heart; b. detecting a pathological initial ventricular and/or atrial rate wherein the atrial rate is greater than or equal to the ventricular rate; c. upon detecting a pathological initial ventricular and/or atrial rate during a first time period: (1) administering an antiarrhythmic cardioactive drug over a second time period; (2) detecting the response of the ventricular and atrial rates to the drug; (3) determining differences between: (a) the ventricular and atrial rates in response to the drug, and (b) the initial atrial and ventricular rates; (4) determining a type of atrial or ventricular arrhythmia from the differences, wherein if the ventricular rate has slowed in response to the drug but the atrial rate has not slowed in response to the drug, an SVT which is not dependent on the AV node is determined. ### Claim 13 A method performed in an implantable system for determining a type of an arrhythmia in a patient's heart, the method including the steps of: a. measuring an initial atrial and ventricular rate of the heart over a first time period; b. monitoring the initial atrial and ventricular rate of the heart for: (1) a pathological initial ventricular rate, and/or (2) a pathological initial atrial rate, c. upon detection of a pathological initial rate: (1) administering a nontherapeutic amount of an antiarrhythmic cardioactive drug during a second time period, the nontherapeutic amount being less than a therapeutic amount typically prescribed for the pathological initial ventricular and/or atrial rate; (2) measuring the response of the atrial and ventricular rate of the heart to the nontherapeutic amount of the drug, (3) comparing the response of the atrial and ventricular rate of the heart to the initial atrial and ventricular rate over a third time period; (4) determining the type of atrial or ventricular arrhythmia from any differences between the response of the atrial and ventricular rate of the heart and the initial atrial and ventricular rate. ### Claim 14 (depends on 13) The method of claim 13 wherein the atrial or ventricular arrhythmia is determined to be an AV nodal dependent SVT if both the ventricular and atrial rates are slowed in response to the drug. ### Claim 15 (depends on 13) The method of claim 13 wherein the atrial or ventricular arrhythmia is determined to be an SVT which is not dependent on the AV node if the ventricular rate has slowed in response to the drug but the atrial rate has not slowed in response to the drug. ### Claim 16 (depends on 13) The method of claim 13 wherein the second time period is 1 to 3 seconds. ### Claim 17 An implantable device for determining a type of an arrhythmia in a patient's heart, the device being configured to: a. monitor initial atrial and ventricular rates of the heart; b. detect a pathological initial ventricular and/or atrial rate; c. administer a nontherapeutic amount of an antiarrhythmic cardioactive drug over a second time period upon detection of a pathological initial ventricular and/or atrial rate during a first time period, the nontherapeutic amount being less than a therapeutic amount typically prescribed for the pathological initial ventricular and/or atrial rate; d. detect the response of the ventricular and atrial rates to the drug; e. determine a type of atrial or ventricular arrhythmia from any differences between: (1) the ventricular and atrial rates in response to the drug, and (2) the initial atrial and ventricular rates. ### Claim 18 (depends on 17) The device of claim 17 wherein the device includes a drug reservoir containing adenosine. ### Claim 19 (depends on 17) The device of claim 17 wherein the device includes a pump in communication with a drug reservoir. ### Claim 20 (depends on 17) The device of claim 17 wherein the drug delivering device is configured to administer the antiarrhythmic cardioactive drug for 1 to 3 seconds during the second time period. ### Claim 21 (depends on 17) The device of claim 17 wherein the device is configured to detect a pathological initial ventricular and/or atrial rate during the first time period if the atrial rate is greater than or equal to the ventricular rate during the first time period. ### Claim 22 An implantable device for determining a type of an arrhythmia in a patient's heart, the device being configured to: a. monitor initial atrial and ventricular rates of the heart; b. detect a pathological initial ventricular and/or atrial rate; c. administer an antiarrhythmic cardioactive drug over a second time period upon detection of a pathological initial ventricular and/or atrial rate during a first time period; d. detect the response of the ventricular and atrial rates to the drug; e. determine a type of atrial or ventricular arrhythmia from any differences between: (1) the ventricular and atrial rates in response to the drug, and (2) the initial atrial and ventricular rates, wherein an AV nodal dependent SVT is determined if both the ventricular and atrial rates are slowed in response to the drug. ### Claim 23 An implantable device for determining a type of an arrhythmia in a patient's heart, the device being configured to: a. monitor initial atrial and ventricular rates of the heart; b. detect a pathological initial ventricular and/or atrial rate; c. administer an antiarrhythmic cardioactive drug over a second time period upon detection of a pathological initial ventricular and/or atrial rate during a first time period; d. detect the response of the ventricular and atrial rates to the drug; e. determine a type of atrial or ventricular arrhythmia from any differences between: (1) the ventricular and atrial rates in response to the drug, and (2) the initial atrial and ventricular rates, wherein an SVT which is not dependent on the AV node is determined if the ventricular rate has slowed in response to the drug but the atrial rate has not slowed in response to the drug.